In the Democratic Republic of the Congo and Uganda, where Bundibugyo Ebola cases are spreading, the World Health Organization has taken a decisive step that signals both urgency and scientific caution: convening expert advisory groups to fast-track clinical trials for candidate vaccines and therapeutics rather than rushing unapproved products into the hands of health workers and patients.
This matters because Bundibugyo virus disease sits in a cruel gap—there are no licensed vaccines or therapeutics specifically approved for preventing or treating it. The virus is rare, but deadly, and the outbreak is unfolding in real time. The WHO's response hinges on a recognition that some candidate products show enough promise to warrant urgent evaluation, but not enough to bypass rigorous testing. It is a calculus between speed and safety, and the path forward runs through clinical trials, not broad deployment.
The WHO convened meetings with its R&D Blueprint technical advisory groups on candidate vaccines and therapeutics, alongside the Strategic Advisory Group of Experts on Immunization and its Ebola vaccine working group. These bodies assessed which products deserved prioritization and recommended that all candidates be used exclusively within clinical trial settings. The R&D Blueprint itself—a global initiative designed to rapidly activate research and development during epidemics—now becomes the backbone of the outbreak response.
What makes this approach distinctive is the coordination across borders and institutions. The WHO is working directly with the governments of the Democratic Republic of the Congo and Uganda to facilitate research evaluation. A consortium including the WHO, both national governments, Africa CDC, ANRS Emerging Infectious Diseases, and other scientific partners is now developing and implementing protocols to assess the safety and efficacy of prioritized therapeutics through field trials. This represents a genuine partnership between global health institutions and national authorities, with affected communities central to the consultation process.
The immediate reality on the ground remains rooted in the fundamentals of outbreak control. The priority, WHO emphasized, continues to be stopping transmission through disease surveillance, rapid testing and diagnosis, contact tracing, isolation and care for patients, infection prevention and control, community engagement, and safe and dignified burials. Clinical trials will run alongside these containment measures, not instead of them.
The friction point is stark and immediate: there is no licensed Ebola vaccine or treatment for Bundibugyo virus disease available to deploy right now. Instead, people affected by the outbreak will enter a research process—one guided by the highest ethical standards, under the leadership of national health authorities and in close consultation with affected communities. WHO has called for accelerated access to essential supplies, stronger community protection and engagement, and coordinated investment in the research and development of Bundibugyo countermeasures.
This path—from outbreak detection to rapid evaluation of promising candidates through clinical trials—represents a shift in how the global health system responds to emerging threats. It is neither the old approach of waiting years for traditional vaccine development, nor the newer impulse to deploy anything that might work in a crisis. Instead, it is an attempt to compress the timeline for evidence-gathering while maintaining scientific rigor. For the people of the Democratic Republic of the Congo and Uganda, the next step is not a licensed vaccine in their arm. It is participation in a carefully designed research process aimed at determining whether the products being evaluated can eventually become the tools that end this outbreak for good.